ClinicalTrials.gg
RecruitingNCT06419439Updated Dec 18, 2025

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

A Phase 2 interventional study of Ketamine hydrochloride and Minimally Enhanced Usual Care in Chronic Low Back Pain and Depression, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Depression by VA Office of Research and Development — 20 open to participants now, 23 under way, 1 of them phase 3. Depression · VA Office of Research and Development.

Planned enrollment
76th of 95
44 · median 120
Started
2025
with 3 others
Phase 2
8 of 101
6 open now
Primary completion
2028-12
later than 12 of 22 live
Registered
91st of 101
by date

Among the 101 studies in Depression by VA Office of Research and Development, this one is the 76th largest by planned enrollment of the 95 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 2, reaches primary completion later than 12 of the 22 other live ones, and was the 91st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

20 of the 101 studies in Depression by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Depression by VA Office of Research and Development, or all of them as a file.
02

Study summary

This is a pilot study to evaluate the feasibility, acceptability, and safety of ketamine infusions followed by a brief behavioral intervention in Veterans with chronic low back pain and depression.

Read the detailed description

Chronic low back pain (CLBP) and depression are top causes of disability in the United States. Veterans are more likely to have both; prevalence is increasing. When CLBP and depression occur together, patients report more functional limitations, unemployment, and higher healthcare spending, and treatment is less successful. Novel approaches simultaneously addressing pain interference and depression symptoms are needed.

This study will involve initial pilot feasibility testing of an intervention designed to help participants with chronic low back pain and depression both reduce pain interference and improve mood. This study will occur in two phases. The initial phase is a open-label single-arm pilot of the combined intervention (ketamine infusions followed by the brief behavioral intervention) in a small sample of Veterans (n=5). The objective is to develop and assess initial feasibility of study procedures and obtain participant feedback through semi-structured exit interviews. The second phase consists of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT.

03

Conditions studied

  • Chronic Low Back Pain
  • Depression

Keywords

  • Feasibility Studies
  • Pilot Projects
  • Randomized Controlled Trials
  • Clinical trials
  • Psychosocial Intervention
  • Narrative Medicine
  • Narrative Therapy
  • Ketamine
  • Ketamine, therapeutic use
  • Veterans
  • Veterans, Research Subjects
  • Low Back Pain, Recurrent/Chronic
  • Depression
  • Hallucinogens, Therapeutic Use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans with self-report of moderate to severe, high impact chronic low back pain (defined as 4/10 in severity via NRS, present 3 months on most days) and associated pain interference (defined as T-score 60 on the PROMIS Pain Interference measure), and current significant depressive symptoms (defined as a score 11 on the Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR).
  • Medically stable (no hospitalizations in the past month lasting 3 days).
  • No changes in pain or depression medication regimen in 4 weeks.
  • No planned surgery, injections, hospitalizations, or other new interventions for back pain (except for physical therapy or exercise) or depression during the next four months (study duration).
  • Participants must have an adult who can drive them home after the ketamine treatments.

Exclusion criteria

Exclusion Criteria:

  • Inability to speak English due to the narrative intervention being conducted in English.
  • Inability or unwillingness to provide written (e.g. current delirium).
  • Current psychotic symptoms, or history of schizophrenia, schizoaffective disorder, and other psychotic disorder.
  • Currently participating in another clinical trial for pain or depression.
  • Current uncontrolled hypertension (defined as systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg).
  • Known elevated intracranial pressure, cerebral arterial aneurysm, or elevated intraocular pressure.
  • History of cirrhosis or unstable cardiac condition (e.g., decompensated congestive heart failure).
  • Any of the following lab values >2x : (ALT), aspartate transferase (AST), direct , alkaline phosphatase, creatinine; thyroid stimulating hormone (TSH) \<2x lower limit of normal or >2x upper limit of normal.
  • Positive urine pregnancy test or lack of method in Veterans of .
  • Known to any in the ketamine injection formulation.
  • Previously experienced serious adverse effects with ketamine.
  • On day of ketamine infusions, a urine drug screen positive for non-prescribed substances(s) (except cannabis) will exclude a participant from receiving ketamine
  • Current or previous abuse of ketamine.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
44 participants (estimated)

Study arms

  • Other
    Open label, single arm pilot

    Initial phase: A small open-label, single arm pilot study (n=5) will be conducted to develop and assess initial feasibility of study procedures and obtain participant feedback through semi-structured exit interviews. All participants in this open-label single arm pilot will receive the intervention (ketamine infusions followed by the brief behavioral intervention). There will be no control condition, randomization, or blinding.

    Drug: Ketamine hydrochloride · Behavioral: Brief narrative intervention

  • Experimental
    Intervention + Minimally Enhanced Usual Care

    Second phase: Intervention arm of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT. Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression.

    Drug: Ketamine hydrochloride · Behavioral: Minimally Enhanced Usual Care · Behavioral: Brief narrative intervention

  • Active comparator
    Minimally Enhanced Usual Care Only

    Second phase: Control arm of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT. Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression.

    Drug: Ketamine hydrochloride · Behavioral: Minimally Enhanced Usual Care

Interventions

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.

  • BehavioralMinimally Enhanced Usual Care

    Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).

    Also known as: Control

  • BehavioralBrief narrative intervention

    Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions. Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention.

    Also known as: Active/intervention

06

What researchers measure

Primary outcomes

  1. Pain Interference (PROMIS Short Form v1.1 Pain Interference 6b)

    Pain interference, defined as the extent to which pain impedes enjoyment of and participation in life activities (including cognitive, social, recreational, and self-care activities), will be the primary outcome. Raw scores (range 6 - 30, higher scores indicating more interference) are normed to mean of general population (T-score 50; SD 10); higher T-scores indicate higher pain interference. Minimum clinically important change is 3.0 - 3.5 point reduction in the T-score.

    Time frame: Visit 7 (8-10 days post randomization)

Secondary outcomes

  1. Pain intensity (Numeric Rating Scale)

    Pain intensity will be measured using the NRS, a single-item measure where participants rate their pain intensity on a scale of 0 (no pain) to 10 (worst pain imaginable). In chronic pain, a reduction of 2 points or 30% is considered a meaningful improvement.

    Time frame: Visit 7 (8-10 days post randomization)

  2. Depression (Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR) )

    The Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR) is a 16-item rating scale assessing self-report of depressive symptoms. Scores range from 0 - 27, with higher scores indicating more severe depressive symptoms. Reductions of approximately 30% are considered clinically meaningful improvements in depressive symptoms.

    Time frame: Visit 7 (8-10 days post randomization)

Other outcomes

  1. Feasibility - Enrollment

    Enrollment benchmarks involve aiming to enroll 2-4 participants/month.

    Time frame: 18 months from start of study

  2. Presence of adverse events (AE)s

    Safety will be assessed via Adverse event (AE) assessment which will be obtained by means of a standard form assessing the presence of AEs.

    Time frame: Visits 1-7 or weekly (whichever is more frequent); Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  3. Pain Interference (PROMIS Short Form v1.1 Pain Interference 6b)

    Pain interference will also be measured at these additional time points. Participants rate each item regarding experiences over the past 7 days on a Likert scale from 1 (not at all) to 5 (Very much). Raw scores (range 6 - 30, higher scores indicating more interference) are normed to mean of general population (T-score 50; SD 10); higher T-scores indicate higher pain interference. Minimum clinically important change is 3.0 - 3.5 point reduction in the T-score.

    Time frame: Visit 1 (Baseline), Visit 5 (post ketamine pre randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  4. Pain Intensity (Numeric Rating Scale)

    Pain intensity will also be measured at these additional time points. Pain intensity will be measured using the NRS, a single-item measure where participants rate their pain intensity on a scale of 0 (no pain) to 10 (worst pain imaginable). In chronic pain, a reduction of 2 points or 30% is considered a meaningful improvement.

    Time frame: Visit 1 (Baseline), Visit 5 (post ketamine pre randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  5. Depression (Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR) )

    Depression will also be measured at these additional time points.

    Time frame: Visit 1 (Baseline), Visit 5 (post ketamine pre randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  6. Acceptability

    Participants will rate acceptability in multiple domains (helpfulness; convenience and comfort; satisfaction) on a 1-4 scale (1=very dissatisfied, 2=somewhat dissatisfied, 3=somewhat satisfied, 4=very satisfied). Benchmarks for acceptability include \>70% "somewhat" or "very satisfied" in all domains.

    Time frame: Visit 7 (8-10 days post randomization)

  7. Global Impression of Change (Patient Global Impression of Change (PGIC))

    Participants rate their change overall on a 7-point Likert scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  8. Cognitive Flexibility (Cognitive Flexibility Scale (CFS))

    Cognitive flexibility refers to individuals' awareness of alternatives to a given situation, willingness to consider them, and belief that they can adapt. Individuals rate 12-items of the Cognitive Flexibility Scale (CFS) on a 6 point Likert scale ranging from 1 (strongly disagree) to 6 (strongly agree), total score range 12 - 72. Higher scores indicate more cognitive flexibility.

    Time frame: Visit 1 (Baseline) , Visit 5 (post ketamine infusions pre randomization), Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  9. Psychological Flexibility (Emotion Regulation Questionnaire (ERQ-9))

    Psychological flexibility refers to individuals' ability to both recognize and accept emotions and choose their subsequent action based on core beliefs and values (rather than a reflexive emotional response). It will be assessed via the 9-item Emotion Regulation Questionnaire (ERQ-9).

    Time frame: Visit 1 (Baseline) , Visit 5 (post ketamine infusions pre randomization), Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  10. Psychological Inflexibility (Acceptance and Action Questionnaire-II (AAQII))

    Psychological inflexibility will be assessed by the 7-item Acceptance and Action Questionnaire-II (AAQII).

    Time frame: Visit 1 (Baseline) , Visit 5 (post ketamine infusions pre randomization), Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  11. Psychologically insightful experiences occurring in response to ketamine administration (Psychological Insight Questionnaire (PIQ))

    The Psychological Insight Questionnaire (PIQ) is a 23-item questionnaire developed to assess acute discoveries or realizations occasioned by a psychedelic experience, such as those regarding one's personality, relationships, behavioral patterns, or emotions. We will use the PIQ to assess changes in response to ketamine.

    Time frame: Visit 5 (post ketamine infusions pre randomization)

  12. Mystical Experiences Occasioned by Ketamine (Mystical Experience Questionnaire (MEQ))

    The Mystical Experience Questionnaire (MEQ) is a 30-item validated measure assessing 4 factors of a mystical or psychedelic experience occasioned by ketamine. These include a mystical experience (e.g., "freedom from the limitations of your personal self and feeling a unity or bond with what was felt to be greater than your personal self"), positive mood (e.g., "sense of awe or awesomeness"), transcendence of time and space, and ineffability (feeling that the experience cannot be conveyed in words).

    Time frame: Visit 5 (post ketamine infusions pre randomization)

  13. Catastrophizing (Catastrophizing Subscale from the Coping Strategies Questionnaire (CSQ-CAT))

    Catastrophizing (the tendency to think of the future as irrationally negative) associates with poor outcomes in the setting of chronic pain, including poorer functional status. It will be measured via the 6-item Catastrophizing Subscale from the Coping Strategies Questionnaire (CSQ-CAT).

    Time frame: Visit 1 (Baseline) , Visit 5 (post ketamine infusions pre randomization), Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  14. Self-Efficacy (PROMIS Self-Efficacy for Chronic Conditions - Managing Daily Activities -Short Form 4a)

    Self-efficacy is a cognitive tendency to perceive oneself as capable of managing life's problems. It will be measured via the 4-item PROMIS Self-Efficacy for Chronic Conditions - Managing Daily Activities -Short Form 4a.

    Time frame: Visit 1 (Baseline) , Visit 5 (post ketamine infusions pre randomization), Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  15. Fear-Avoidance Beliefs/Kinesiophobia (Fear-Avoidance Beliefs Questionnaire-Physical Activity Subscale (FABQ-PA))

    Fear-avoidance beliefs refers to the cognitive appraisal that certain kinds of activities may cause additional damage or pain; more fear-avoidance beliefs for physical activity (also called kinesiophobia) predict development of chronic pain and disability in those with acute low back pain. Fear-avoidance beliefs will be measured using the 4-item Fear-Avoidance Beliefs Questionnaire-Physical Activity Subscale (FABQ-PA).

    Time frame: Visit 1 (Baseline) , Visit 5 (post ketamine infusions pre randomization), Visit 7 (8-10 days post randomization), Visit 8 (1 month follow up), Visit 9 (3 month follow up)

  16. Nociplastic Pain Characteristics (Fibromyalgia Survey Questionnaire (FSQ))

    The Fibromyalgia Survey Questionnaire (FSQ), adapted from the American College of Rheumatology Fibromyalgia Survey score, will be used to measure pain widespreadness and accompanying symptoms, also known as nociplastic features. It consists of two scales, the Widespread Pain Index (WPI) and the Symptom Severity score (SSS). The WPI instructs participants to indicate location(s) of pain (range 0 - 19, higher scores indicate more areas of pain). The SS score assesses additional symptoms including fatigue, unrefreshing sleep, and cognitive disruption (range 0 -12, higher scores indicate more symptoms). Total score range is 0 - 31, with higher scores indicating more nociplastic features of pain. Fibromyalgia screening positive cut points are WPI \>=7 and SSS \>=5 OR WPI of 4-6 and SSS \>= 9.

    Time frame: Visit 1 (Baseline)

  17. Neuropathic Pain Characteristics (painDETECT)

    PainDETECT will be used to evaluate presence of neuropathic features of back pain. PainDETECT instructs individuals to rate pain at different time points (range 0 - 10, with higher scores indicating more severe pain), and to select/rate agreement with items on a Likert scale from never to very strongly. Total score range is 0 - 38, with those scoring \>18 having likely neuropathic components of back pain.

    Time frame: Visit 1 (Baseline)

  18. Feasibility - retention/attendance

    Target \>70% of participants who complete baseline measures will complete all four ketamine infusion sessions, the behavioral intervention (if assigned) and the initial post-intervention assessment battery.

    Time frame: Visit 7 (8-10 days post randomization)

  19. Feasibility - measurement completion

    Target \>80% of participants complete follow-up assessments.

    Time frame: Visit 9 (3 month follow up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

Of 144 non-industry phase 2 interventional studies under Depression, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 35 months is close to that.

Counting every sponsor, half of 198 studies reached it within 31 months; a quarter within 18 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
May 17, 2024
StartActual
Dec 3, 2025
Primary completionEst.
Dec 1, 2028
CompletionEst.
Jun 30, 2029
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06419439
Responsible party
Sponsor
First posted
May 17, 2024
Start date
Dec 3, 2025
Primary completion
Dec 1, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Dec 18, 2025

Study contacts

Victoria D Powell, MD
Contact
Victoria.Powell2@va.gov
(734) 845-3072
Sarah L Krein, PhD RN
Contact
Sarah.Krein@va.gov
(734) 845-3621
Victoria D Powell, MD
principal investigator · VA Ann Arbor Healthcare System, Ann Arbor, MI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion